Clinical Trial Update: X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for X-396 capsule in ALK-positive non-small cell lung cancer patients previously treated with crizotinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• X-396

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN